Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Molecular diagnosis & therapy - 1 Aug 2016

Ali Mohamed A M

Abstract excerpt

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first malignancy in which a unique chromosomal abnormality was identified and a pathophysiologic association was suggested. The hallmark of CML is a reciprocal chromosomal translocation between the long arms of chromosomes 9 and 22, t(9; 22)(q34; q11),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Targeted Therapy

Share to Neoplastic Stem Cells

Share to Retreatment

Share to Treatment Failure

Source

Identifiers

PMID: 27220498
DOI: 10.1007/s40291-016-0208-1

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.PMID 27220498Read ↗

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringSemantic proximity Read ↗

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

New and established tyrosine kinase inhibitors for chronic myeloid leukemiaSemantic proximity Read ↗

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

BCR-ABL: The molecular mastermind behind chronic myeloid leukemiaSemantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.